

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905 B2
APPLICATION NO. : 10/747742
DATED : September 7, 2010
INVENTOR(S) : Mark Tawa, Orn Almarsson and Julius F. Remenar

Page 1 of 35

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 60, "if their were" should read --if there were--.

Column 22,

Line 16, "(⁸1995-2002, Materials Data, Inc." should read
--(⁸1995-2002, Materials Data, Inc.)--.

Line 63, "(D 2001" should read -© 2001--.

Column 24,

Line 24, "gly solvate" should read --glycol solvate--.

Column 27, Table 3,

Column "API Chemical Name", Row "(-)-amlodipine",
"3-ethyl-S-methyl ester" should read --3-ethyl-5-methyl ester--.


Column 30, Table 3,

Column "Example of Indication", Row "5-azacitidine",
"Myelodysplastic" should read --Myelodysplastic--.

Column 31, Table 3,

Column "CAS No.", Row "AC-5216",
"2627-69-2" should read --blank--.

Signed and Sealed this
Nineteenth Day of April, 2011

A handwritten signature in black ink that reads "David J. Kappos". The signature is written in a cursive, flowing style.

David J. Kappos
Director of the United States Patent and Trademark Office

U.S. Pat. No. 7,790,905 B2

Column 33, Table 3,

Column “API Chemical Name”, Row “acrivastine + pseudoephedrine”,
 “[S-(R*,R)]-” should read --[S-(R*,R*)]- --.

Column “API Chemical Name”, Row “Adenoscan”,
 “6-Amino-9-β-D-nbofuranosyl-9H-purine [CAS]” should read
 --6-Amino-9-β-D-ribofuranosyl-9H-purine [CAS]--.

Column 37, Table 3,

Column “API Chemical Name”, Row “alzapride”,
 “1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl)methyl]- [CAS]” should read
 --1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl)methyl]- [CAS]--.

Column “API Chemical Name”, Row “alprazolam”,
 “4H-[1,2,4]Triazolo[4,3-al][1,4]benzodiazepine” should read
 --4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine--.

Column 38, Table 3,

Column “Example of Therapeutic Use”, Row “alfuzosin”,
 “modivied-release” should read --modified-release--.

Column 39, Table 3,

Column “API Generic Name”, “Amdinociiiin Pivoxil” should read --Amdinocillin Pivoxil--.

Column 40, Table 3,

Column "Example of Indication", Row "AMD-3100",
"leocopenia" should read --leucopenia--.

Column 41, Table 3.

Row "Aminoguanidine".

“API Chemical Name	CAS No.”	should read	--API Chemical Name	CAS No.--
79-17-4				79-17-4

Column 47, Table 3.

Column "API Chemical Name", Row "aprepitant",

“5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]” should read --5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]--.

Column 49, Table 3.

Column "API Chemical Name", Row "artemotil",

"12+62,12aR*)]-[CAS]" should read --12β,12aR*)]- [CAS]--.

Column 50, Table 3.

Column "Example of Therapeutic Use", Row "atenolol",

"Antihypeertensive" should read --Antihypertensive--.

Column 52, Table 3.

Column "Example of Indication", Row "AZD-4282",

"Pain, neuronpathic" should read --Pain, neuropathic--.

U.S. Pat. No. 7,790,905 B2

Column 53, Table 3,

Column "API Generic Name", "aziocillin" should read --azlocillin--.

Column "API Chemical Name", Row "balofloxacin",

"3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-pipendinyl]-4-oxo-[CAS]" should read

--3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo- [CAS]--.

Column "API Generic Name", "bamidipine" should read --barnidipine--.

Column "API Chemical Name", Row "betahistine",

"2-Pyndineethanamine" should read --2-Pyridineethanamine--.

Column 58, Table 3,

Column "Example of Therapeutic Use", Row "benzydamine",

"Stomatologic
reproductive,
inflammatory"

should read

--Stomatological
reproductive/gonadal,
anti-inflammatory--.

Column "Example of Therapeutic Use", Row "biapenem",

"Beta-lactam antibic" should read --Beta-lactam antibiotic--.

Column 59, Table 3,

Column "API Generic Name", "Betamiverine" should read --Bietamiverine--.

Column 59, Table 3,

Column "API Chemical Name", Row "bimosiamose",

"(1,1-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]" should read

--(1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]--.

Column 61, Table 3,

Column "API Chemical Name", Row "bosentan",

"Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2-bipynmidin]-4-yl]-[CAS]" should read

--Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- [CAS]--.

Column 63, Table 3,

Column "API Chemical Name", Row "brivudin",

"Uridine, 5-(2-bromoethenyl)-2-deoxy, (E)-[CAS]" should read

--Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 66, Table 3,

Row “bunazosin”,	“Example of Therapeutic Use Antihypertens	Example of Indication”
should read	--Example of Therapeutic Use Antihypertensive, adrenergic	Example of Indication--.
		Hypertension, general

Column 67, Table 3,

Column “API Generic Name”,
“Calciuhi Mesoxalate” should read --Calcium Mesoxalate--.

Column 69, Table 3,

Column “API Chemical Name”, Row “camptothecin”,
“4-Ethyl-4-hydroxy-1H-pyrano-[13'4':6,7]indolizinol[1,2-b;]quinoline-
3,14(4H,12H)-dione microemulsion” should read
--4-Ethyl-4-hydroxy-1H-pyrano-[13'4':6,7]indolizinol[1,2-b;]quinoline-
3,14(4H,12H)-dione--.

Column 71, Table 3,

Column “API Chemical Name”, Row “carmustine”,
“Urea, N,N-bis(2-chloroethyl)-N-nitroso- [CAS]” should read
--Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]--.

Column 73, Table 3,

Column “API Chemical Name”, Row “cefalexin”,
“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-
[(aminophenylacetyl)amino]-3-methyl-oxo-, [CAS]” should read
--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-
[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [CAS]--.
Column “CAS No.”, Row “cefalexin”, “8105879-42-3” should read --105879-42-3--.

Column 75, Table 3,

Column “API Chemical Name”, Row “cefmetazole”,
“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]
acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,
(6R-cis)-[CAS]” should read
--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]
acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,
(6R-cis)- [CAS]--.
Column “API Chemical Name”, Row “cefonicid”,
“[6R-[6Alpha,7B(R)]]-[CAS]” should read --[6R-[6Alpha,7β(R*)]]- [CAS]--.
Column “API Chemical Name”, Row “cefoperazone”,
“[6R-[6Alpha,7β(R*)]]-[CAS]” should read --[6R-[6Alpha,7β(R*)]]- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 75, Table 3,

Column "API Chemical Name", Row "cefpirimazole",

"[6R-[6Alpha,7betaR*)]]-[CAS]" should read --[6R-[6Alpha,7beta(R*)]]- [CAS]--.

Column 77, Table 3,

Column "API Chemical Name", Row "cefpirome",

"[6R-[6Alpha,711(Z)]]-[CAS]" should read --[6R-[6Alpha,7beta(Z)]]- [CAS]--.

Column "API Chemical Name", Row "cefuroxime axetil",

"5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

3-[[[(aminocarbonyl)oxy]methyl]-7-[(2-furanyl(methoxyimino)acetyl]amino]-8-oxo-," should read

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

3-[[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo--,--.

Column 78, Table 3,

Column "Patent Reference", Row "cefroxadine",

"143511" should read --1435111--.

Column "Patent Reference", Row "cefsulodin",

"138765" should read --1387656--.

Column "Patent Reference", Row "ceftazidime",

"202539" should read --2025398--.

Column 81, Table 3,

Column "API Generic Name", "Chlorproethazine" should read --Chlorproethazine--.

Column "API Generic Name", "Chlorquinaldol" should read --Chlorquinaldol--.

Column 83, Table 3,

Column "API Chemical Name", Row "choline-L-alfoscerate",

"Ethanaminium, 2-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]xy]-N,N,N-trimethyl-," should read

--Ethanaminium, 2-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl--,--.

Column 85, Table 3,

Column "API Generic Name", "cispiatin" should read --cisplatin--.

Column 89, Table 3,

Column "API Chemical Name", Row "CMI-392",

"Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran"

should read

--Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran--.

Column "API Chemical Name", Row "CMT-3",

"(4a5,5aR,12a5)-[CAS]" should read --(4aS,5aR,12aS)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 89, Table 3,

Column "API Chemical Name", Row "CNI-1493",
 "Decanediamide, N,N-bis[3,5-bis[1-[(aminoiminomethyl)hydrazono]
 ethyl]phenyl]-, tetrahydrochloride [CAS]" should read
 --Decanediamide, N,N'-bis [3,5-bis[1-[(aminoiminomethyl)hydrazono]
 ethyl]phenyl]-, tetrahydrochloride [CAS]--.

Column 90, Table 3,

Column "Example of Indication", Row "clopidogrel",
 "myocardia" should read --myocardial--.

Column 91, Table 3,

Column "API Chemical Name", Row "CNS-5161",
 "N-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-methylthio)phenyl]guanidine
 [CAS]" should read
 --N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-methylthio)phenyl]guanidine
 [CAS]--.

Column 92, Table 3,

Row "CP-461",	"Example of Therapeutic Use Anticancer, other	Example of Indication"
should read	--Example of Therapeutic Use Anticancer, other	Example of Indication--. Cancer, prostate

Column 92, Table 3,

Row "CRL-5861",	"Example of Therapeutic Use Antisickling	Example of Indication"
should read	--Example of Therapeutic Use Antisickling	Example of Indication--. Anaemia, sickle cell

Column 95, Table 3,

Column "API Chemical Name", Row "cymserine",
 "(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl
 ester [CAS]" should read
 --(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl
 ester [CAS]--.

Column "API Chemical Name", Row "cyproterone",
 "(1 β ,2 β)-6-Chloro-1,2-dihydro-17-hydroxy-3H-cyclopropa[1,2]pregna-1,4,6-
 triene-3,20-dione [CAS]" should read
 --(1 β ,2 β)-6-Chloro-1,2-dihydro-17-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-
 triene-3,20-dione [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 95, Table 3,

Column "API Chemical Name", Row "dalfopristin + quinupristin",
 "mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-pipendinecarboxylic acid)virginiamycin S1- [CAS]" should read
 --mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid)virginiamycin S1- [CAS]--.

Column 97, Table 3,

Row "DB-67",

"API Generic Name"	API Chemical Name"
DB-67	7-tert-Butyldimethylsiyl-10-
hydroxy-	
camptothecin	

should read

--API Generic Name	API Chemical Name--.
DB-67	7-tert-Butyldimethylsiyl-10-hydroxycamptothecin

Column 99, Table 3,

Column "API Generic Name", "Delmadinane" should read --Delmadinone--.

Column 100, Table 3,

Row "dersalazine",

"Example of Therapeutic Use"	Example of Indication"
Anti-inflammatory	

should read

--Example of Therapeutic Use	Example of Indication--.
Anti-inflammatory	Colitis, ulcerative

Column 101, Table 3,

Column "API Chemical Name", Row "dextrazoxane",

"2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (5)- [CAS]" should read
 --2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)- [CAS]--.

Column "API Chemical Name", Row "dextropropoxyphene",

"[S-(R,S*)]-[CAS]" should read --[S-(R*,S*)]- [CAS]--.

Column "API Chemical Name", Row "dibekacin",

"D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]1-2-deoxy-, sulfate (salt)[CAS]" should read
 --D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 105, Table 3,

Column "API Generic Name", "Diisapropylamine" should read --Diisopropylamine--.

Column "API Chemical Name", Row "dinoprostone",

"Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z, 11 Alpha, 13E, 15S)-[CAS]" should read

--Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11 Alpha,13E,15S)-[CAS]--.

Column "API Generic Name", "Dioxethednne" should read --Dioxethedrine--.

Column 107, Table 3,

Column "API Generic Name", "Dastigmine" should read --Distigmine--.

Column "API Chemical Name", Row "DK-507k",

"(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate" should read

--(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinccarboxylic acid hydrochloride monohydrate--.

Column "API Chemical Name", Row "dofetilide",

"Methanesulfonamide, N-[4-[2-[methyl[2-[4[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-[CAS]" should read

--Methanesulfonamide, N-[4-[2-[methyl[2-[4[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]- [CAS]--.

Column 108, Table 3,

Column "Example of Therapeutic Use", Row "docusate",

"Formulation, derm" should read --Formulation, dermal, topical--.

Column 109, Table 3,

Column "API Generic Name", "Domiodoi" should read --Domiodol--.

Column "API Generic Name", "darzolamide" should read --dorzolamide--.

Column "API Chemical Name", Row "dorzolamide + timolol",

"4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (5), (Z)-2-butenedioate (1:1) (salt) [CAS]" should read

--4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2-butenedioate (1:1) (salt) [CAS]--.

Column 113, Table 3,

Column "API Chemical Name", Row "E-1010",

"1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochionde, (4R,5S,6S)-[CAS]" should read

--1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 113, Table 3,

Column "API Chemical Name", Row "E-2101",

"N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide"

should read

--N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide--.

Column "API Chemical Name", Row "E-5842",

"Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]" should read

--Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]--.

Column 115, Table 3,

Column "API Generic Name",

"Edetate Calcium Disodium" should read --Edetate Calcium Disodium--.

Column 116, Table 3,

Column "Example of Therapeutic Use", Row "eflucimibe",

"Hypolipaemic/Antitherosclerosis" should read

--Hypolipaemic/Antiatherosclerosis--.

Column 118, Table 3,

Column "Example of Therapeutic Use", Row "enoxacin",

"Quinolone antibacter" should read

--Quinolone antibacterial--.

Column 119, Table 3,

Column "API Chemical Name", Row "eperisone",

"1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidiny)- [CAS]" should read

--1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidiny)- [CAS]--.

Column "API Generic Name", "Epicillin" should read --Epicillin--.

Column "API Generic Name", "Epinzole" should read --Epirizole--.

Row "Epitiostanol",

"API Chemical CAS No."

Name

2363-58-8

should read

--API Chemical CAS No.--.

Name

2363-58-8

Column "API Chemical Name", Row "eptaplatin",

"Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4',kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)-[CAS]" should read

--Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 119, Table 3,

Row “Eptastigmine”,

“API Chemical Name	CAS No.”
-----------------------	----------

101246-68-8

should read

--API Chemical Name	CAS No.-- 101246-68-8
------------------------	--------------------------

Column 121, Table 3,

Column “API Chemical Name”, Row “escitalopram”,

“(5)- [CAS]” should read --(S)- [CAS]--.

Column “API Generic Name”, “Etafedrine” should read --Etafedrine--.

Column 123, Table 3,

Column “API Generic Name”, “Etilefnn” should read --Etilefrin--.

Column 125, Table 3,

Column “API Chemical Name”, Row “exatecan”,

“10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-diane, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]” should read

--10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]--.

Column 125, Table 3,

Column “API Chemical Name”, Row “exemestane”,

“Androsta-1,4-diene-3,17-diane, 6-methylene-[CAS]” should read

--Androsta-1,4-diene-3,17-dione, 6-methylene- [CAS]--.

Column “API Chemical Name”, Row “ezetimibe”,

“2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-[CAS]” should read

--2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- [CAS]--.

Column 129, Table 3,

Column “API Generic Name”, “Ferrous Gluconate” should read --Ferrous Gluconate--.

Column “API Chemical Name”, Row “ferumoxitol”,

“Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite Imaging agent”

should read

--Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite--.

Column “API Chemical Name”, Row “fexofenadine”,

“Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]” should read

--Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 129, Table 3,

Column "API Chemical Name", Row "fidarestat",

"Spiro(4H-1-benzopyran-4,4-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]" should read

--Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]--.

Column 131, Table 3,

Column "API Generic Name",

"Fludeoxyglucose F1B" should read --Fludeoxyglucose F18--.

Column "API Chemical Name", Row "flurbiprofen",

"[1,1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-[CAS]" should read

--[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]--.

Column 133, Table 3,

Column "API Chemical Name", Row "flutazolam",

"Oxazolo[3,2-d][1,4]benzodiazepin-6(SH)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)-[CAS]" should read

--Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]--.

Column 135, Table 3,

Column "API Chemical Name", Row "fumagiline",

"[3R-(3Alpha,4Alpha(2R*,3R*),5β,6β(all-E))]- [CAS]" should read

--[3R-[3Alpha,4Alpha(2R*,3R*),5β,6β(all-E))]- [CAS]--.

Column 137, Table 3,

Column "API Generic Name", "Gepef rifle" should read --Gepefrine--.

Column 138, Table 3,

Column "Example of Therapeutic Use", Row "gallium nitrate",

"Osteoporosh" should read --Osteoporosis treatment--.

Column 139, Table 3,

Column "API Chemical Name", Row "gimatecan",

"dimethylethoxyimino]methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3,4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione" should read

--(4S)-11-[(E)-[(1,1-dimethylethoxy)imino] methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione--.

Column "API Generic Name", "Giyburide" should read --Glyburide--.

Column 141, Table 3,

Column "API Generic Name", "griseofuvin" should read --griseofulvin--.

Column "API Chemical Name", Row "GYK1-16084",

"(+)-R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyridazinone hydrochloride" should read

--(+)-R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyridazinone hydrochloride--.

U.S. Pat. No. 7,790,905 B2

Column 143, Table 3,

Column "API Generic Name", "HGP-6" should read --HGP-6[^]--.

Column 145, Table 3,

Column "API Generic Name",

"Hydroxychloroquine" should read --Hydroxychloroquine--.

Column "API Chemical Name", Row "hyoscyamine",

"benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-B-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo]," should read

--benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo]--.

Column "API Chemical Name", Row "ibopamine",

"Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester-[CAS]" should read

--Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester-[CAS]--.

Column 147, Table 3,

Column "API Chemical Name", Row "indeloxazine",

"Morptioline" should read --Morpholine--.

Column 149, Table 3,

Column "API Chemical Name", Row "indinavir",

"D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R*),2Alpha]]-, [CAS]" should read

--D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R*),2Alpha]]-, [CAS]--.

Column "API Chemical Name", Row "indisulam",

"1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-[CAS]" should read

--1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]--.

Column 151, Table 3,

Column "API Chemical Name", Row "irofulven",

"Spiro[cyclopropane-1,5-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)-[CAS]" should read

--Spiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]--.

Column "API Chemical Name", Row "isepamicin",

"D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]" should read

--D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 152, Table 3,

Column "Example of Indication", Row "isepamicin",

"Infection, fungal, general" should read --Infection, dermatological--.

Column 153, Table 3,

Column "API Chemical Name", Row "israpafant",

"6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]" should read

--6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]--.

Column 155, Table 3,

Column "API Chemical Name", Row "JTV-519",

"1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinylpropyl]- [CAS]" should read

--1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinylpropyl]- [CAS]--.

Column "API Chemical Name", Row "KCB-328",

"Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]" should read

--Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]--.

Column 157, Table 3,

Column "API Generic Name", "KUL7211" should read --KUL-7211--.

Column "API Chemical Name", Row "L-758298",

"Phosphonic acid, [3-fl(2R,3S)-2-.(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS]" should read

--Phosphonic acid, [3-[[2(2R,3S)-2-.(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS]--.

Column "API Chemical Name", Row "landiolol",

"Benzenepropanoic acid, 4-[2-hydroxy-3-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, should read

--Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[(4-Morpholinylcarbonyl)amino]ethyl]amino]propoxy]-,--.

Column "API Chemical Name", Row "laniquidar",

"Methyl 6,11-dihydro-11-11-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate" should read

--Methyl 6,11-dihydro-11-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate--.

U.S. Pat. No. 7,790,905 B2

Column 159, Table 3.

Column "API Chemical Name", Row "lasofoxifene",

"2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-(5R-cis)-, (5-(R*, R*)))-2,3-dihydroxybutanedioate [CAS]" should read

--2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-(5R-cis)-, (S-(R*, R*)))-2,3-dihydroxybutanedioate [CAS]--.

Column "API Chemical Name", Row "levamisole",

"Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (5)-[CAS]" should read

--Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]--.

Column 160, Table 3.

Column "Example of Therapeutic Use", Row "LAX-111",

"Neuroleptic" should read --Neuroleptic--.

Column 161, Table 3.

Column "API Chemical Name", Row "levetiracetam",

"1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (5)-[CAS]" should read

--1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]--.

Column "API Chemical Name", Row "levobupivacaine",

"2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (5)-[CAS]"

should read

--2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]--.

Column 161, Table 3.

Column "API Chemical Name", Row "levodropropizine",

"1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (5)-[CAS]" should read

--1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]--.

Column "API Chemical Name", Row "levofloxacin",

"7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (5)-[CAS]" should read

--7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]--.

Column "API Chemical Name", Row "levomoprolol",

"2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (5)-[CAS]"

should read

--2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]--.

Column "API Chemical Name", Row "levosimendan",

"Propanedinitrile, (14-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono]-, (R)- [CAS]" should read

--Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)-[CAS]--.

Column 163, Table 3.

Column "API Chemical Name, Row "liranaftate",

"Garbamothioic acid" should read --Carbamothioic acid--.

Column "API Chemical Name, Row "lisinopril",

"(5)- [CAS]" should read --(S)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 163, Table 3,

Column "API Chemical Name", Row "LLUAlpha",

"S-2,7,8-Trimethyl-6-(11-carboxyethyl)-6-hydroxychroman" should read

--S-2,7,8-Trimethyl-6-(β-carboxyethyl)-6-hydroxychroman--.

Column 164, Table 3,

Row "lobaplatin",

**Example of
Therapeutic Use**
Anticancer alkylatin

Example of Indication"

should read

--**Example of
Therapeutic Use**
Anticancer alkylating

Example of Indication--.

Cancer, lung, small cell

Column 165, Table 3,

Column "API Chemical Name", Row "loratadine",

"1-Pipendinecarboxylic acid" should read

--1-Piperidinecarboxylic acid--.

Column 167, Table 3,

Column "API Chemical Name", Row "Iurtotccan",

"11H-1,4-Dioxino[2,3-g]pyrano[3,4:6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione," should read

--11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolinc-9,12[8H,14H]-dione,--.

U.S. Pat. No. 7,790,905 B2

Column 170, Table 3,

Column "Example of Indication", Row "maribavir",
 "Cancer, pancreatic" should read --Infection, cytomegalovirus--.

Column 171, Table 3,

Column "API Chemical Name", Row "meluadrine",
 "(R*,R*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]" should read
 --(R*,R*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]--.

Column 173, Table 3,

Column "API Generic Name", "mepartncin" should read --mepartricin--.
 Column "API Generic Name", "Methotnmeprazine" should read --Methotrimcprazine--.

Column 175, Table 3,

Row "Methylergonovine",

"API Chemical	CAS No."	should read	--API Chemical	CAS No.--.
Name			Name	113-42-8
113-42-8				

Column 177, Table 3,

Column "API Generic Name", "Metnzamide" should read --Metrizamide--.

Column 179, Table 3,

Column "API Chemical Name", Row "misoprostol",
 "Prost-13-en-1-oic acid, 11,16-dihydro 16-methyl-9-oxo-," should read
 --Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo--,--.

U.S. Pat. No. 7,790,905 B2

Column 183, Table 3,

Column "API Chemical Name", Row "mycophenolate mofetil",

"4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-", should read

--4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl--,.

Column 185, Table 3,

Column "API Chemical Name", Row "naltrexone",

"(5Alpha)-[CAS]" should read --(5Alpha)-[CAS]--.

Column 186, Table 3,

Row "NAMI",

**"Example of
Therapeutic Use**

Anticancer, other

should read

**--Example of
Therapeutic Use**

Anticancer, other

**Example of"
Indication**

Example of--.

Indication

Cancer, general

Column 187, Table 3,

Column "API Generic Name", "NGX-4016" should read --NCX-4016--.

Column "API Chemical Name", Row "nicaraven",

"3-Pyridinecarboxamide, N,N-(1-methyl-1,2-ethanediyl)bis-[CAS]" should read

--3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediyl)bis- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 189, Table 3,

Column “API Chemical Name”, Row “nicorandil”,

“3-Pyridinecarboxamide” should read --3-Pyridinecarboxamide--.

Column “API Chemical Name”, Row “nicotine”,

“Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-[CAS]” should read

--Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]--.

Column “API Chemical Name”, Row “niperotidine”,

“[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine” should read

--N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine--.

Column 191, Table 3,

Column “API Chemical Name”, Row “NM-3”,

“3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumann” should read

--3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin--.

Column “API Generic Name”,

“N-Methylepinephrine” should read --N-Methylepinephrine--.

Column 192, Table 3,

Column “Example of Indication”, Row “nitisinone”,

“Cirrhosis” should read --Cirrhosis, hepatic--.

Column 193, Table 3,

Column “API Generic Name”, “Norelgestramin, Ethinyl Estradiol” should read

--Norelgestromin, Ethinyl Estradiol--.

U.S. Pat. No. 7,790,905 B2

Column 193, Table 3.

Column "API Generic Name", "Norgestnenone" should read --Norgestrienone--.

Column "API Chemical Name", Row "NV-07",

"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]" should read

--2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]--.

Column 194, Table 3.

Column "Example of Therapeutic Use", Row "NS-220",

"Hypolipaeamic/Antitherosclerosis" should read

--Hypolipaeamic/Antiatherosclerosis--.

Column 195, Table 3.

Column "API Generic Name", "Octavenne" should read --Octaverine--.

Column "API Chemical Name", Row "octenidine",

"1-Octanamine, N,N-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis-[CAS]" should read

--1-Octanamine, N,N'-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis- [CAS]--.

Column "API Chemical Name", Row "olmesartan medoxomil",

"1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-," should read

--1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,--.

Column 195, Table 3.

Column "API Chemical Name", Row "omiloxetine",

"Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]" should read

--Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]--.

Column 196, Table 3.

Column "Example of Therapeutic Use", Row "Omacor",

"Hypolipaeamic/Antitherosclerosis" should read

--Hypolipaeamic/Antiatherosclerosis--.

Column 197, Table 3.

Column "API Chemical Name", Row "OPC-51803",

"(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide" should read

--(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide--.

Column "API Chemical Name", Row "Org-12962",

"Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]" should read

--Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 197, Table 3,

Column "API Chemical Name", Row "ornoprostil",

"Prost-13-en-1-oic acid, 11,15-dihydro-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)-[CAS]" should read

--Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]--.

Column 198, Table 3,

Row "OPC-31260",

"Example of Therapeutic Use Unspecified	Example of' Indication
--	-----------------------------------

should read

--Example of Therapeutic Use Urological	Example of--. Indication Unspecified
--	---

Column 200, Table 3,

Column "Example of Therapeutic Use", Row "oxandrolone",

"Reproductive/gonad" should read --Reproductive/gonadal, general--.

Column 201, Table 3,

Column "API Generic Name", "Oxypinocemphone" should read --Oxypinocamphone--.

Column 201, Table 3,

Column "API Chemical Name", Row "palindore",

"2(S)-, (2E)-2-butendioate (1:1)" should read

--2(S)-, (2E)-2-butendioate (1:1)--.

Column "API Chemical Name", Row "palonosetron",

"3a5-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride" should read

--3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride--.

Column 202, Table 3,

Row "PAI inhbs",

"Example of Therapeutic Use Antithrombotic	Example of' Indication
---	-----------------------------------

should read

--Example of Therapeutic Use Antithrombotic	Example of--. Indication Thrombosis, venous
--	--

Column 205, Table 3,

Column "API Chemical Name", Row "pentamidine",

"Benzenecarboximidamide, 4,4'-[1,5-pentanedylbis(oxy)]bis-[CAS]" should read

--Benzenecarboximidamide, 4,4'-[1,5-pentanedylbis(oxy)]bis- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 205, Table 3,

Column "API Chemical Name", Row "peplomycin",

"(5)-[CAS]" should read --(S)- [CAS]--.

Column "API Generic Name", "Pencyazine" should --Pericyazine--.

Column 206, Table 3,

Column "Example of Therapeutic Use", Row "pentostatin",

"Anticancer, anticancer, antimetabolite" should read

--Anticancer, antimetabolite--.

Column 207, Table 3,

Column "API Generic Name", "Penmethazine" should --Perimethazine--.

Column "API Chemical Name", Row "perisoxal",

"1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]" should read

--1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]--.

Column "API Generic Name", "Pertapine" should read --Perlapine--.

Column "API Generic Name", "Permethnn" should read --Permethrin--.

Column "API Generic Name", "PH-b" should read --PH-10--.

Column "API Generic Name", "Phenetunde" should read --Pheneturide--.

Column "API Generic Name", "Phenglutanmide" should read --Phenglutarimide--.

Column 209, Table 3,

Column "API Generic Name", "Phenopendine" should read --Phenoperidine--.

Column "API Generic Name", "Pholednne" should read --Pholedrine--.

Column "API Generic Name", "pibaserod" should read --piboserod--.

Column "API Generic Name", "Picopenne" should read --Picoperine--.

Column 211, Table 3,

Column "API Chemical Name", Row "pimilprost",

"Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha (1E,3S,5S),5β,6aAlpha]]-[CAS]" should read

--Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha (1E,3S*,5S*),5β,6aAlpha]]- [CAS]--.

Column "API Chemical Name", Row "pioglitazone",

"2,4-Thiazolidinedione, 5-[(4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochloride (+/-)-[CAS]" should read

--2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochloride (+/-)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 213, Table 3,

Column "API Generic Name", "Pipenlate" should read --Piperilate--.

Column "API Generic Name", "pipenne analogues" should read --piperine analogues--.

Column "API Chemical Name", Row "pirmenol",

"(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidiny)propyl]-

.Alpha.phenyl-, cis-(+)-[CAS]" should read

--(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidiny)propyl]-

.Alpha.phenyl-, cis-(+)- [CAS]--.

Column "API Chemical Name", Row "piroxicam betadex",

"(β-Cyclodextrin" should read --β-Cyclodextrin--.

Column "API Chemical Name", Row "piroxicam cinnamate",

"5,5-dioxide [CAS]" should read --S,S-dioxide [CAS]--.

Column 215, Table 3,

Column "API Generic Name",

"pivampicillin/pivmecillinam" should read --pivampicillin/pivmecillinam--.

Column "API Chemical Name", Row "pivmecillinam",

"[2S-(2Alpha,5Alpha,6β)]-[CAS]" should read

--[2S-(2Alpha,5Alpha,6β)]- [CAS]--.

Column 217, Table 3,

Column "API Generic Name",

"Potassium Permanganate" should read --Potassium Permanganate--.

Column "API Chemical Name", Row "pramipexole",

"(5)- [CAS]" should read --(S)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 218, Table 3,

Row “pralosartan”,

**“Example of
Therapeutic Use
Antihypertensive,**

**Example of
Indication**

should read

**--Example of
Therapeutic Use
Antihypertensive,
renin system**

**Example of--
Indication
Hypertension, general**

Column 219, Table 3,

Column “API Chemical Name”, Row “pregabalin”,

“Hexanoic acid, 3-(aminomethyl)-5-methyl, (5)-[CAS]” should read

--Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]--.

Column “API Chemical Name”, Row “Premarin + trimegestone”,

“Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [1711 (5)]-[CAS]” should read

--Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17B (S)]-[CAS]--.

Column 221, Table 3,

Column “API Generic Name”,

“propionyl L-carnitine” should read --propionyl L-carnitine--.

Column 221, Table 3,

Row “propiverine”,

**“API Chemical
Name**

CAS No.”

2,2-diphenyl-2-(1-propoxy)
acetic acid
(1-methylpiperid-4-yl)
ester54556-98-8
hydrochloride

60569-19-9

should read

**--API Chemical
Name**

CAS No.--.

2,2-diphenyl-2-(1-propoxy)
acetic acid
(1-methylpiperid-4-yl)
ester hydrochloride

54556-98-8

60569-19-9

Column “API Generic Name”, “Propylhexedrine” should read --Propylhexedrine--.

Column “API Chemical Name”, Row “proxigermanium”,

“Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediy)bis-[CAS]” should read

--Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediy)bis- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 223, Table 3,

Column "API Chemical Name", Row "pseudoephedrine + triprolidine",
 "mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine
 monohydrochloride [CAS]" should read
 --mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine
 monohydrochloride [CAS]--.

Column "CAS No.", Row "pseudoephedrine",
 "90-82-4, 8054-271, 345-78-8" should read --90-82-4, 8054-27-1, 345-78-8--.

Row "PX-12",

API Generic Name	API Chemical Name"
PX-12 disulfide	1-Methylpropyl 2-mercaptoimidazolyl

should read

--API Generic Name	API Chemical Name--.
PX-12	1-Methylpropyl 2-mercaptoimidazolyl disulfide

Column "API Generic Name", "Pyenthione" should read --Pyrrithione--.

Column "API Generic Name", "Pyronandine" should read --Pyronaridine--.

Column "API Generic Name", "Pyrrolnitnn" should read --Pyrrolnitrin--.

Column 223, Table 3,

Column "API Chemical Name", Row "quetiapine",
 "Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperaziny)ethoxy]-, (F)-2-
 butenedioate (2:1) (salt) [CAS]" should read
 --Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperaziny)ethoxy]-, (E)-2-
 butenedioate (2:1) (salt) [CAS]--.

Column "API Generic Name", "quinacnne" should read --quinacrine--.

Column 224, Table 3,

Column "Example of Indication", Row "quinacrine",
 "Creutzfeldt-Jakob disease" should read --Creutzfeldt-Jakob disease--.

Column 225, Table 3,

Column "API Chemical Name", Row "quinaprilat",
 "3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-
 oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]-[CAS]" should read
 --3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-
 oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]- [CAS]--.

Column "API Chemical Name", Row "ramipril",

"Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-
 phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R)],2Alpha,3aβ,6aβ]]-
 [CAS]" should read
 --Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenyl
 propyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aβ,6aβ]]-
 [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 225, Table 3,

Column "API Chemical Name", Row "ranitidine",

"1,1-Ethenediamine, N-[2-([5-[(dimethylamino)methyl]-2-furanyl)methyl]thioethyl]-N'-methyl-2-nitro-[CAS]" should read

--1,1-Ethenediamine, N-[2-([5-[(dimethylamino)methyl]-2-furanyl)methyl]thioethyl]-N'-methyl-2-nitro- [CAS]--.

Column "API Chemical Name", Row "ranolazine",

"1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+/-)-[CAS]" should read

--1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]--.

Column 227, Table 3,

Column "API Generic Name", "raxofeist" should read --raxofelast--.

Column "API Chemical Name", Row "repaglinide",

"Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (5)-[CAS]" should read

--Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]--.

Column "API Chemical Name", Row "R-flurbiprofen",

"[1,1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl" should read

--[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl--.

Column 227, Table 3,

Column "API Generic Name",

"Rho (D) Immune Globuhn (Human)" should read

--Rho (D) Immune Globulin (Human)--.

Column "API Chemical Name", Row "rifaximin",

"[2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]" should read

--[2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]--.

Column 231, Table 3,

Column "API Chemical Name", Row "ropivacaine",

"2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (5)-[CAS]"

should read

--2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]--.

Column "API Chemical Name", Row "rotigotine",

"1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (5)-[CAS]" should read

--1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]--.

Column 233, Table 3,

Column "API Chemical Name", Row "rubitecan",

"1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (5)-[CAS]" should read

--1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 235, Table 3,

Column "API Chemical Name", Row "saquinavir",

"Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinoliny]carbonyl)amino]-, [3S-[CAS]]" should read

--Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinoliny]carbonyl)amino]-, [3S-[2[1R*(R*),2S*],3A α ,4a β ,8a β]]- [CAS]--.

Column 237, Table 3,

Column "API Chemical Name", Row "Sch-63390",

"7H-Pyrazolo[4,3-e][1,2,4]tnazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)-[CAS]" should read

--7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]--.

Column "API Generic Name", "SGS technology" should read --SCS technology--.

Column 237, Table 3,

Row "seratrodast",

"API Chemical Name	CAS No."
-------------------------------	-----------------

Benzeneheptanoic acid,	1103187-07-1
------------------------	--------------

zeta-(2,4,5-trimethyl-3,6-	112665-43-7
----------------------------	-------------

dioxo-1,4-cyclohexadien-	
-yl)-, (+/-)-[CAS]	

should read

--API Chemical Name	CAS No.--
--------------------------------	------------------

Benzeneheptanoic acid,	103187-07-1
------------------------	-------------

zeta-(2,4,5-trimethyl-3,6-	112665-43-7
----------------------------	-------------

dioxo-1,4-cyclohexadien-	
1-yl)-, (+/-)- [CAS]	

Column "API Chemical Name", Row "sertindole",

"2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-pipendiny]ethyl]-[CAS]" should read

--2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidiny]ethyl]- [CAS]--.

Column 240, Table 3,

Column "Example of Therapeutic Use", Row "silver sulfadiazine",

"Anti-infective" should read --Anti-infective, other--.

U.S. Pat. No. 7,790,905 B2

Column 239, Table 3,

Column "API Chemical Name", Row "sivelestat",

"Glycine, N-[2-D[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino] benzoyl]-[CAS]" should read

--Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino] benzoyl]- [CAS]--.

Column 241, Table 3,

Column "API Chemical Name", Row "SN-38",

"(4S)-4,7,11-trimethyl-3,4,12,14-tetrahydro-4, 10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl" should read

--(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl--.

Column "API Chemical Name", Row "soblidotin",

"L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-L-2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*(1S*,2S*)]]-[CAS]" should read

--L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*(1S*,2S*)]]-[CAS]--.

Column "API Chemical Name", Row "sodium oxybate",

"Butync acid" should read --Butyric acid--.

Column "API Chemical Name", Row "sodium prasterone sulfate",

"3B-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)" should read

--3β-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)--.

U.S. Pat. No. 7,790,905 B2

Column 241, Table 3,

Column “API Chemical Name”, Row “sofalcone”,

“Acetic acid, [5-((3-methyl-2-butenyl)oxy)-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]-[CAS]” should read
 --Acetic acid, [5-[(3-methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]--.

Column 243, Table 3,

Column “API Chemical Name”, Row “SR-146131”,

“1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]” should read
 --1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]--.

Column “API Chemical Name”, Row “β-alethine”,

“Propanamide, N, N(dithiodi-2,1-ethanediyl)bis(3-amino)-[CAS]” should read
 --Propanamide, N, N'(dithiodi-2,1-ethanediyl)bis(3-amino)- [CAS]--.

Column 245, Table 3,

Column “API Generic Name”, “Stiibamidine” should read --Stilbamidine--.

Column 247, Table 3,

Column “API Chemical Name”, Row “sufentanil”,

“Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-pipendinyl]-N-phenyl-[CAS]” should read
 --Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 247, Table 3,

Column "API Chemical Name", Row "sulbenicillin",

"4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6a(S*)]]-[CAS]"

should read

--4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6β(S*)]]- [CAS]--.

Column "API Generic Name", "Sulfaguanole" should read --Sulfaguanole--.

Column "API Generic Name", "Sulfapyndine" should read --Sulfapyridine--.

Column 249, Table 3,

Column "API Chemical Name", Row "sultamicillin",

"5, 5-dioxide," should read --S, S-dioxide,--.

Column "API Chemical Name", Row "sultopride",

"Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-[CAS]" should read

--Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]--.

Column 251, Table 3,

Column "API Chemical Name", Row "T-1095",

"1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-B-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]" should read

--1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-β-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]--.

Column 251, Table 3,

Column "API Chemical Name", Row "T-1249",

"L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl [CAS]"

should read

--L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]--.

Column "API Chemical Name", Row "TA-2005",

"2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, manahydrochloride, [R-(R*,R*)]-[CAS]" should read

--2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 251, Table 3.

Column "API Chemical Name", Row "TA-993",

"1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-)-, (2Z)-2-butenedioate [CAS]" should read

--1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-)-, (2Z)-2-butenedioate [CAS]--.

Column "API Chemical Name", Row "tacalcitol",

"9,10-Secachalesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)- [CAS]" should read

--9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)- [CAS]--.

Column "API Chemical Name", Row "tacedinaline",

"Benzamide, 4-(acetylamin)-N-(2-aminophenyl)-[CAS]" should read

--Benzamide, 4-(acetylamin)-N-(2-aminophenyl)- [CAS]--.

Column "API Generic Name", "Tacralimus" should read --Tacrolimus--.

Column "API Chemical Name", Row "tadalafil",

"Pyrazina(1',2':1,6)pyrida(3,4-b)indole1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]" should read

--Pyrazino(1',2':1,6)pyrido(3,4-b)indole1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]--.

Column 251, Table 3.

Column "API Chemical Name", Row "tafenoquine",

"1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoramethyl)phenoxy]-8-quinoliny]- [CAS]" should read

--1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinoliny]- [CAS]--.

Column "API Generic Name", "taflupaside" should read --tafluposide--.

Column "API Chemical Name", Row "TAK-375",

"(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-bifuran-8-yl])propionamide"

should read

--(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide--.

Column 253, Table 3.

Column "API Chemical Name", Row "taltirelin",

"L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)-[CAS]" should read

--L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]--.

Column "API Chemical Name", Row "tamsulosin",

"Benzenesulfonamide, 5-12-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)-[CAS]" should read

--Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]--.

U.S. Pat. No. 7,790,905 B2

Column 253, Table 3,

Column "API Chemical Name", Row "tecastemizole",
 "1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-pipendinyl- [CAS]"
 should read
 --1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl-
 [CAS]--.

Column 254, Table 3,

Column "Example of Therapeutic Use", Row "talaporfin",
 "Radio/chemosensitizer" should read --Radio/chemosensitizer--.

Column 255, Table 3,

Column "API Chemical Name", Row "tedisamil",
 "Spiro[cyclopentane-1,9-[3,7]diazabicyclo[3.3.1]nonane],
 3',7'-bis(cyclopropylmethyl)-[CAS]" should read
 --Spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane],
 3',7'-bis(cyclopropylmethyl)- [CAS]--.

Column "API Chemical Name", Row "telbivudine",
 "β-L-2-deoxythymidine" should read --β-L-2'-deoxythymidine--.

Column "API Chemical Name", Row "telmisartan",
 "(1,1'-Biphenyl)-2-carboxylic acid" should read
 --(1,1'-Biphenyl)-2-carboxylic acid--.

Column 255, Table 3,

Column "API Chemical Name", Row "tenatoprazole",
 "1H-Imidazo(4,5-b)pyndine" should read --1H-Imidazo(4,5-b)pyridine--.

Column "API Chemical Name", Row "teniposide",
 "Furo[3',4':6,7]naphthol[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-
 hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-β-D-
 glucopyranosyl]oxy]-, [5R-[5Alpha,5aβ,8aAlpha,9β(R*)]]-[CAS]" should read
 --Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-
 hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylcne)-β-D-
 glucopyranosyl]oxy]-, [5R-[5Alpha,5aβ,8aAlpha,9β(R*)]]- [CAS]--.

Column 257, Table 3,

Column "API Chemical Name", Row "terfenadine",
 "1-Pipendinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-
 (hydroxydiphenylmethyl)-[CAS]" should read
 --1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-
 (hydroxydiphenylmethyl)- [CAS]--.

Column "API Chemical Name", Row "terguride",
 "Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]-[CAS]" should read
 --Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]- [CAS]--.

Column 259, Table 3,

Column "API Generic Name", "thiacymsenne" should read --thiacymserine--.

Column "CAS No.", Row "Thimerfonate", "5964249" should read --5964-24-9--.

Column "API Generic Name", "Tiadenoi" should read --Tiadenol--.

U.S. Pat. No. 7,790,905 B2

Column 259, Table 3,

Column "API Chemical Name", Row "tianeptine",

"5,5-dioxide [CAS]" should read --S,S-dioxide [CAS]--.

Column 261, Table 3,

Column "API Generic Name", "Tinondine" should read --Tinoridine--.

Column 265, Table 3,

Column "API Chemical Name", Row "travoprost",

"1-methylethylester (1R(1Alpha(Z),2B(1E,3R*),3Alpha,5Alpha) [CAS]"

should read

--1-methylethylester (1R(1Alpha(Z),2B(1E,3R*),3Alpha,5Alpha) [CAS]--.

Column "API Chemical Name", Row "trazodone",

"1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinylopropyl]- [CAS]" should read

--1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinylopropyl]- [CAS]--.

Column 269, Table 3,

Column "API Chemical Name", Row "trimipramine",

"5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,11-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]" should read

--5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,β-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]--.

Column 269, Table 3,

Column "API Chemical Name", Row "trofosfamide",

"3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphonn 2-oxide" should read

--3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide--.

Column 271, Table 3,

Row "Valnoctamide",

"API Chemical	CAS No."
Name	

4171-13-5

should read

--API Chemical	CAS No.--.
Name	4171-13-5

Column 271, Table 3,

Column "API Generic Name", "Vaiproic Acid" should read --Valproic Acid--.

U.S. Pat. No. 7,790,905 B2

Column 272, Table 3,

Row “tyloxapol”,

**“Example of
Therapeutic Use**
Formulation, inhalable,
topical

**Example of
Indication**

should read

**--Example of
Therapeutic Use**
Formulation, inhalable,
topical

Example of--.
Indication
Cystic fibrosis

Column 273, Table 3,

Column “API Chemical Name”, Row “vecuronium”,

“Piperidinium, 1-bis(acetyloxy)-2-(1-piperidinylandrostan-1 6-yl)-1-methyl-, [CAS]” should read

--Piperidinium, 1-[(2 β ,3 α ,5 α ,16 β ,17 β)-3,17-bis(acetyloxy)-2-(1-piperidinylandrostan-16-yl)-1-methyl-, [CAS]--.

Column “API Chemical Name”, Row “venlafaxine”,

“Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]”

should read

--Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]--.

Column 275, Table 3,

Column “API Chemical Name”, Row “vinorelbine”,

“C'-Norvincaleukoblastine, 3,4'-didehydro-4'-deoxy-[CAS]” should read

--C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]--.

Column 275, Table 3,

Column “API Chemical Name”, Row “vinpocetine”,

“Ebumamenine-14-carboxylic acid, ethyl ester, (3 α ,16 α)-[CAS]”

should read

--Ebumamenine-14-carboxylic acid, ethyl ester, (3 α ,16 α)- [CAS]--.

Column “API Generic Name”, “vonconazole” should read --voriconazole--.

Column 277, Table 3,

Column “API Generic Name”, “Yahimbine” should read --Yohimbine--.

Column 278, Table 3,

Row “YT-146”,

**“Example of
Therapeutic Use**
Anti-inflammation,
general

**Example of
Indication**

should read

**--Example of
Therapeutic Use**
Anti-inflammatory

Example of--.
Indication
Inflammation, general

U.S. Pat. No. 7,790,905 B2

Column 280, Table 3,

Row “zinc acetate”,

**“Example of
Therapeutic Use**
Antiviral, other
virus prophylaxis

**Example of”
Indication**

should read

**--Example of
Therapeutic Use**
Antiviral, other

Example of--.
Indication
Infection, herpes simplex
virus prophylaxis

Column 279, Table 3,

Column “API Chemical Name”, Row “zolmitriptan”,

“(S)-[CAS]” should read --(S)- [CAS]--.